Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma-Reference-Cited by-同舟云学术

Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma

Published:2019-07-22 Issue:15 Volume:134 Page:1238-1246
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Stephens Deborah M.¹^ORCID,Li Hongli²,Schöder Heiko³,Straus David J.³,Moskowitz Craig H.³,LeBlanc Michael²,Rimsza Lisa M.⁴,Bartlett Nancy L.⁵,Evens Andrew M.⁶^ORCID,LaCasce Ann S.⁷^ORCID,Barr Paul M.⁸^ORCID,Knopp Michael V.⁹^ORCID,Hsi Eric D.¹⁰,Leonard John P.¹¹,Kahl Brad S.⁵,Smith Sonali M.¹²,Friedberg Jonathan W.⁸

Affiliation:

1. Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT;

2. SWOG Statistical Center, Seattle, WA;

3. Memorial Sloan Kettering Cancer Center, New York, NY;

4. Mayo Clinic, Scottsdale, AZ;

5. Oncology Division, Washington University in St. Louis, St. Louis, MO;

6. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;

7. Dana-Farber Cancer Institute, Boston, MA;

8. Division of Hematology/Oncology, University of Rochester, Rochester NY;

9. Division of Hematology, The Ohio State University, Columbus, OH;

10. Cleveland Clinic, Cleveland, OH;

11. Weill Cornell Medical Center, New York, NY; and

12. Section of Hematology/Oncology, University of Chicago, Chicago, IL

Abstract

AbstractThe investigators present results on the long-term value and limitations of early interim positron emission tomography (PET) scanning in advanced Hodgkin lymphoma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/15/1238/1223458/bloodbld2019000719.pdf

Reference37 articles.

1. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin’s disease: report of an intergroup trial;Duggan;J Clin Oncol,2003

2. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496);Gordon;J Clin Oncol,2013

3. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG);Sieniawski;Blood,2008

4. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study;Engert;J Clin Oncol,2009

5. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group;Borchmann;Lancet Oncol,2017

Cited by 99 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2-deoxy-2-[18F]FDG PET Imaging for Therapy Assessment in Hodgkin’s and Non-Hodgkin Lymphomas;PET Clinics;2024-10

2. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

3. Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD;Frontiers in Oncology;2024-09-05

4. Advanced stage classic Hodgkin lymphoma (cHL): biology, clinical features, therapeutic approach, and management at relapse;Leukemia & Lymphoma;2024-09-03

5. Efficacy of escalating therapy with brentuximab vedotin‐AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD;Hematological Oncology;2024-08-12